Ankündigung • May 12
Ambea AB (Publ) Approves Dividend for the Financial Year 2025, Payable on 20 May 2026 Ambea AB (publ) at its Annual General Meeting held on May 12, 2026, adopted the annual report for the financial year 2025 and resolved on a dividend of SEK 2.65 per share. 15 May 2026 was established as record day for dividend. The dividend is expected to be paid out to the shareholders on 20 May 2026. Ankündigung • May 07
Ambea AB (publ) to Report Q4, 2026 Results on Feb 11, 2027 Ambea AB (publ) announced that they will report Q4, 2026 results on Feb 11, 2027 Ankündigung • Apr 07
Ambea AB (Publ) Announces Declines Re-Election of Samuel Skott as Director Ambea AB (publ) announced that Samuel Skott has declined re-election to the board at annual general meeting to be held on 14 May 2025. Ankündigung • Mar 10
Ambea AB (publ) to Report Fiscal Year 2025 Results on Mar 31, 2026 Ambea AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Mar 31, 2026 Ankündigung • Nov 28
Ambea AB (publ), Annual General Meeting, May 12, 2026 Ambea AB (publ), Annual General Meeting, May 12, 2026. Ankündigung • Aug 28
An undisclosed buyer acquired 5.10% stake in Ambea AB (publ) (OM:AMBEA) from Peder Pråhl for approximately SEK 540 million. An undisclosed buyer acquired 5.10% stake in Ambea AB (publ) (OM:AMBEA) from Peder Pråhl for approximately SEK 540 million on August 27, 2025. A cash consideration valued at SEK 126 per share will be paid for 4.3 million shares.
An undisclosed buyer completed the acquisition of 5.10% stake in Ambea AB (publ) (OM:AMBEA) from Peder Pråhl on August 27, 2025. Ankündigung • Apr 02
Ambea AB (publ) (OM:AMBEA) completed the acquisition of Invalidiliiton Asumispalvelut Oy from Invalidiliitto Ry. Ambea AB (publ) (OM:AMBEA) entered into an agreement to acquire Invalidiliiton Asumispalvelut Oy from Invalidiliitto Ry for approximately SEK 1.40 billion on March 12, 2025. The purchase price is SEK 1.38 billion on a cash and debt-free basis. The transaction is expected to lead to transaction costs of approximately SEK 30 million in 2025. Expected integration and other nonrecurring costs are estimated at around SEK 40 million, evenly distributed between 2025 and 2026. Transaction is anticipated to have a positive impact on EBITA starting in 2025 and will contribute positively to earnings per share from 2026 onward The acquisition adds approximately 50 care units across Finland, with around 1,400 beds and more than 2,600 employees, to the Ambea Group. SEK 217 million of the consideration is payable in 2 million shares in Ambea which Ambea currently holds in treasury and the remainder in cash. The seller has entered a lock-up undertaking, with customary exceptions, in favor of Ambea for a period of 12 months. Ambea has secured a Term Loan facility of SEK 990 million to finance the transaction. After completion of the acquisition, Ambea's leverage ratio including Validia measured as Net Debt/adjusted EBITDA excluding IFRS 16 is expected to be approximately 2.8x. Validia’s current management team will continue to lead the business, with the Managing Director of Validia reporting directly to Ambea’s Chief Executive Officer & President and joining the Ambea Group Management Team upon the completion of the transaction. For the period ending December 31, 2024, Invalidiliiton Asumispalvelut Oy reported total revenue of SEK 1.4 billion.
The transaction is not subject to regulatory approvals and is expected to close April 1, 2025.
Evli Corporate Finance AB acted as financial advisor for Ambea AB. Christina Kokko, Gustav Persson, Eva Fredrikson, Siri Blomberg, Sofie Bjärtun, Joel Magnusson, Albert Wållgren, Josefine Lanker, Marcus Glader and Sebastian Örndahl of Advokatfirman Vinge Stockholm Ab acted as legal advisor for Ambea AB. Krogerus Attorneys Ltd. acted as legal advisor for Ambea AB. CountOn Oy act as financial advisor for Invalidiliitto Ry.
Ambea AB (publ) (OM:AMBEA) completed the acquisition of Invalidiliiton Asumispalvelut Oy from Invalidiliitto Ry on April 1, 2025. Following the transfer, and as of the date of closing, Ambea owns 6,000,000 shares in the Company. Ankündigung • Mar 21
Ambea AB (Publ) Announces Daniel Björklund Decline Re-Election as Board Member Ambea AB (publ) announced Daniel Björklund has declined re-election as Board Members. Ankündigung • Mar 13
Ambea AB (publ) (OM:AMBEA) entered into an agreement to acquire Invalidiliiton Asumispalvelut Oy from Invalidiliitto Ry for approximately SEK 1.40 billion. Ambea AB (publ) (OM:AMBEA) entered into an agreement to acquire Invalidiliiton Asumispalvelut Oy from Invalidiliitto Ry for approximately SEK 1.40 billion on March 12, 2025. The purchase price is SEK 1.38 billion on a cash and debt-free basis. The transaction is expected to lead to transaction costs of approximately SEK 30 million in 2025. Expected integration and other nonrecurring costs are estimated at around SEK 40 million, evenly distributed between 2025 and 2026. Transaction is anticipated to have a positive impact on EBITA starting in 2025 and will contribute positively to earnings per share from 2026 onward The acquisition adds approximately 50 care units across Finland, with around 1,400 beds and more than 2,600 employees, to the Ambea Group. SEK 217 million of the consideration is payable in 2 million shares in Ambea which Ambea currently holds in treasury and the remainder in cash. The seller has entered a lock-up undertaking, with customary exceptions, in favor of Ambea for a period of 12 months. Ambea has secured a Term Loan facility of SEK 990 million to finance the transaction. After completion of the acquisition, Ambea's leverage ratio including Validia measured as Net Debt/adjusted EBITDA excluding IFRS 16 is expected to be approximately 2.8x. Validia’s current management team will continue to lead the business, with the Managing Director of Validia reporting directly to Ambea’s CEO & President and joining the Ambea Group Management Team upon the completion of the transaction. For the period ending December 31, 2024, Invalidiliiton Asumispalvelut Oy reported total revenue of SEK 1.4 billion. The transaction is not subject to regulatory approvals and is expected to close April 1st, 2025. Evli Corporate Finance AB acted as financial advisor for Ambea AB. Christina Kokko, Gustav Persson, Eva Fredrikson, Siri Blomberg, Sofie Bjärtun, Joel Magnusson, Albert Wållgren, Josefine Lanker, Marcus Glader and Sebastian Örndahl of Advokatfirman Vinge Stockholm Ab acted as legal advisor for Ambea AB. Krogerus Attorneys Ltd. acted as legal advisor for Ambea AB. Ankündigung • Feb 26
Ambea AB (publ) announces Annual dividend, payable on May 21, 2025 Ambea AB (publ) announced Annual dividend of SEK 2.0000 per share payable on May 21, 2025, ex-date on May 15, 2025 and record date on May 16, 2025. Recent Insider Transactions • Nov 12
Director recently sold €160k worth of stock On the 8th of November, Daniel Björklund sold around 19k shares on-market at roughly €8.56 per share. This transaction amounted to 7.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €94k more than they sold in the last 12 months. Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: kr3.14 (vs kr2.30 in 3Q 2023) Third quarter 2024 results: EPS: kr3.14 (up from kr2.30 in 3Q 2023). Revenue: kr3.59b (up 7.0% from 3Q 2023). Net income: kr266.0m (up 29% from 3Q 2023). Profit margin: 7.4% (up from 6.1% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 11
Ambea AB (publ) Announces Appointments to Nomination Committee Ambea AB (publ) announced that The Nomination Committee ahead of the 2025 consists of Jakob Rikwide Bolero Holdings Sarl, Chair of the Nomination Committee, Anette Dahlberg, Första AP-fonden, Niclas Röken, Alcur Fonder and Yrjö Närhinen, Chair of Ambea AB (publ). The Nomination Committee shall perform the duties of the Nomination Committee as set out in the Code, which, among other things, includes proposals for appointment of board members, chairman of the board and auditor. The Nomination Committee will also propose remuneration to the board members. The Nomination Committee’s proposals shall be presented in the convening notice made public before each annual shareholders’ meeting. Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.51 in 2Q 2023) Second quarter 2024 results: EPS: kr1.10 (up from kr0.51 in 2Q 2023). Revenue: kr3.56b (up 7.6% from 2Q 2023). Net income: kr95.0m (up 107% from 2Q 2023). Profit margin: 2.7% (up from 1.4% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 16
Ambea AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 Ambea AB (publ) announced that they will report fiscal year 2024 results at 7:00 AM, Central European Standard Time on Feb 12, 2025 Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €6.45, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 2.9% over the past three years. Ankündigung • May 16
Ambea AB (Publ) Approves Dividend, Payable on 22 May 2024 Ambea AB (publ) at its AGM held on May 15, 2024 resolved on a dividend of SEK 1.50 per share. Friday 17 May 2024 was established as record day for dividend. The dividend is expected to be paid out to the shareholders on Wednesday 22 May 2024. Upcoming Dividend • May 09
Upcoming dividend of kr1.50 per share Eligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (3.0%). Reported Earnings • May 03
First quarter 2024 earnings released: EPS: kr1.25 (vs kr0.77 in 1Q 2023) First quarter 2024 results: EPS: kr1.25 (up from kr0.77 in 1Q 2023). Revenue: kr3.53b (up 9.0% from 1Q 2023). Net income: kr111.0m (up 59% from 1Q 2023). Profit margin: 3.1% (up from 2.2% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Ankündigung • Apr 12
Ambea AB (Publ) Proposes Dividend, Payable on 22 May 2024 Ambea AB (publ) at its AGM to be held on May 15, 2024 proposed dividend to the shareholders of SEK 1.50 per share and that 17 May 2024 shall be the record date for dividend payments. If the Annual General Meeting resolves in accordance with the proposal, the dividend is expected to be paid out through Euroclear Sweden AB on 22 May 2024. Declared Dividend • Apr 07
Dividend of kr1.50 announced Shareholders will receive a dividend of kr1.50. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 27%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 58% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Apr 04
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to €5.59. The fair value is estimated to be €4.54, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has grown by 7.7%. For the next 3 years, revenue is forecast to grow by 4.0% per annum. Earnings are also forecast to grow by 15% per annum over the same time period. Ankündigung • Mar 29
Ambea AB (publ) to Report Q3, 2024 Results on Nov 06, 2024 Ambea AB (publ) announced that they will report Q3, 2024 results at 7:00 AM, Central European Standard Time on Nov 06, 2024 Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: kr5.07 (vs kr3.89 in FY 2022) Full year 2023 results: EPS: kr5.07 (up from kr3.89 in FY 2022). Revenue: kr13.3b (up 5.4% from FY 2022). Net income: kr455.0m (up 24% from FY 2022). Profit margin: 3.4% (up from 2.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Mar 17
Director recently bought €89k worth of stock On the 14th of March, Daniel Björklund bought around 17k shares on-market at roughly €5.34 per share. This transaction amounted to 7.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €479k more in shares than they have sold in the last 12 months. Ankündigung • Mar 13
Contemplated Sale of Shares of ACTR Holding AB in Ambea AB Carnegie Investment Bank AB (publ) ("Carnegie") and Danske Bank A/S, Denmark, Sweden Branch ("Danske Bank") have been retained by ACTR Holding AB ("ACTR") to explore the opportunity to sell approximately 7.7 million shares in Ambea AB (publ) (OM:AMBEA) ("Ambea") (the "Placing"). ACTR currently holds 17.12% of the total number of shares and votes in Ambea. The price per share in the Placing will be determined through an accelerated book-building process. The book-building period commences immediately after publication of this press release and may close at any time on short notice. Subject to customary exceptions or obtaining consent from Carnegie and Danske Bank, ACTR has agreed to a lock-up until publication of Ambea's next interim report, which is expected to be published on 3 May 2024, in relation to its shares in Ambea following the potential Placing. ACTR is controlled by Triton Fund III (via its general partner), which is managed by Triton Investment Management Limited, which is in turn advised by Triton Investments Advisers LLP. Carnegie and Danske Bank are acting as Joint Bookrunners in connection with the Placing. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €5.08, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 25% over the past three years. Reported Earnings • Feb 08
Full year 2023 earnings released: EPS: kr5.07 (vs kr3.89 in FY 2022) Full year 2023 results: EPS: kr5.07 (up from kr3.89 in FY 2022). Revenue: kr13.6b (up 7.5% from FY 2022). Net income: kr455.0m (up 24% from FY 2022). Profit margin: 3.4% (up from 2.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • Jan 27
Ambea AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024 Ambea AB (publ) announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Mar 27, 2024 Recent Insider Transactions • Dec 04
Director recently bought €134k worth of stock On the 28th of November, Daniel Björklund bought around 35k shares on-market at roughly €3.83 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €405k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: kr2.30 (vs kr2.04 in 3Q 2022) Third quarter 2023 results: EPS: kr2.30 (up from kr2.04 in 3Q 2022). Revenue: kr3.42b (up 7.2% from 3Q 2022). Net income: kr206.0m (up 6.7% from 3Q 2022). Profit margin: 6.0% (down from 6.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Aug 22
CEO & President recently bought €18k worth of stock On the 17th of August, Mark Jensen bought around 6k shares on-market at roughly €3.06 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mark has been a buyer over the last 12 months, purchasing a net total of €187k worth in shares. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: kr0.51 (vs kr0.91 in 2Q 2022) Second quarter 2023 results: EPS: kr0.51 (down from kr0.91 in 2Q 2022). Revenue: kr3.31b (up 5.3% from 2Q 2022). Net income: kr46.0m (down 47% from 2Q 2022). Profit margin: 1.4% (down from 2.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • Aug 04
Ambea AB (publ) to Report Q2, 2023 Results on Aug 17, 2023 Ambea AB (publ) announced that they will report Q2, 2023 results at 7:00 AM, Central European Standard Time on Aug 17, 2023 Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €3.33, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 20x in the Healthcare industry in Germany. Total loss to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.79 per share. Ankündigung • May 12
Ambea AB (publ) Approves Dividend Payable on 19 May 2023 Ambea AB (publ) at the Annual General Meeting resolved on a dividend of SEK 1.25 per share. 15 May 2023 was established as record day for dividend. The dividend is expected to be paid out to the shareholders on 19 May 2023. Upcoming Dividend • May 05
Upcoming dividend of kr1.25 per share at 3.0% yield Eligible shareholders must have bought the stock before 12 May 2023. Payment date: 19 May 2023. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (3.2%). Reported Earnings • May 05
First quarter 2023 earnings released: EPS: kr0.77 (vs kr0.70 in 1Q 2022) First quarter 2023 results: EPS: kr0.77 (up from kr0.70 in 1Q 2022). Revenue: kr3.28b (up 6.5% from 1Q 2022). Net income: kr70.0m (up 6.1% from 1Q 2022). Profit margin: 2.1% (in line with 1Q 2022). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €3.26, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 22x in the Healthcare industry in Germany. Total loss to shareholders of 19% over the past three years. Recent Insider Transactions • Apr 03
CEO & President recently bought €35k worth of stock On the 29th of March, Mark Jensen bought around 12k shares on-market at roughly €2.91 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mark has been a buyer over the last 12 months, purchasing a net total of €151k worth in shares. Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: kr3.89 (vs kr2.51 in FY 2021) Full year 2022 results: EPS: kr3.89 (up from kr2.51 in FY 2021). Revenue: kr12.6b (up 10% from FY 2021). Net income: kr366.0m (up 54% from FY 2021). Profit margin: 2.9% (up from 2.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Feb 14
CEO & President recently bought €25k worth of stock On the 9th of February, Mark Jensen bought around 8k shares on-market at roughly €3.15 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €28k. Mark has been a buyer over the last 12 months, purchasing a net total of €116k worth in shares. Reported Earnings • Feb 10
Full year 2022 earnings released: EPS: kr3.89 (vs kr2.51 in FY 2021) Full year 2022 results: EPS: kr3.89 (up from kr2.51 in FY 2021). Revenue: kr13.0b (up 13% from FY 2021). Net income: kr366.0m (up 54% from FY 2021). Profit margin: 2.8% (up from 2.1% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Ankündigung • Feb 09
Ambea AB (Publ) Proposes Dividend for the Year 2022 Ambea AB (publ)'s Board proposed a dividend of SEK 1.25 (1.15) per share for 2022. Ankündigung • Jan 11
Ambea AB (publ) to Report Q3, 2023 Results on Nov 02, 2023 Ambea AB (publ) announced that they will report Q3, 2023 results at 7:00 AM, Central European Standard Time on Nov 02, 2023 Ankündigung • Dec 06
Ambea AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023 Ambea AB (publ) announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Mar 28, 2023 Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent Director Gunilla Rudebjer was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Nov 04
Third quarter 2022 earnings released: EPS: kr2.04 (vs kr2.01 in 3Q 2021) Third quarter 2022 results: EPS: kr2.04 (up from kr2.01 in 3Q 2021). Revenue: kr3.24b (up 11% from 3Q 2021). Net income: kr193.0m (up 1.6% from 3Q 2021). Profit margin: 6.0% (down from 6.5% in 3Q 2021). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • Oct 22
Ambea AB (publ), Annual General Meeting, May 12, 2023 Ambea AB (publ), Annual General Meeting, May 12, 2023. Location: Vardaga Villa Solhem, Avestagatan 31, 163 53 Stockholm Sweden Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: kr0.91 (vs kr0.39 in 2Q 2021) Second quarter 2022 results: EPS: kr0.91 (up from kr0.39 in 2Q 2021). Revenue: kr3.27b (up 15% from 2Q 2021). Net income: kr86.0m (up 132% from 2Q 2021). Profit margin: 2.6% (up from 1.3% in 2Q 2021). Over the next year, revenue is forecast to grow 3.8%, compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 06
Upcoming dividend of kr1.15 per share Eligible shareholders must have bought the stock before 13 May 2022. Payment date: 19 May 2022. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (2.6%). Reported Earnings • May 05
First quarter 2022 earnings released: EPS: kr0.70 (vs kr0.49 in 1Q 2021) First quarter 2022 results: EPS: kr0.70 (up from kr0.49 in 1Q 2021). Revenue: kr3.12b (up 14% from 1Q 2021). Net income: kr66.0m (up 44% from 1Q 2021). Profit margin: 2.1% (up from 1.7% in 1Q 2021). Over the next year, revenue is forecast to grow 6.2%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Liselott Kilaas was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: kr2.51 (vs kr3.80 in FY 2020) Full year 2021 results: EPS: kr2.51 (down from kr3.80 in FY 2020). Revenue: kr11.5b (up 3.6% from FY 2020). Net income: kr237.0m (down 34% from FY 2020). Profit margin: 2.1% (down from 3.2% in FY 2020). Over the next year, revenue is forecast to grow 5.8%, compared to a 4.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Ankündigung • Feb 16
Lena Hofsberger and Liselott Kilaas Chooses Not to Stand for Re-Election of Ambea's Board Ambea AB (publ) announced that Lena Hofsberger and Liselott Kilaas have chosen to not stand for re-election, at its upcoming annual general meeting 2022. Lena Hofsberger has been board member in the company since 2012 and chair of the board since 2013. Reported Earnings • Feb 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr2.51 (down from kr3.80 in FY 2020). Revenue: kr11.7b (up 5.3% from FY 2020). Net income: kr237.0m (down 34% from FY 2020). Profit margin: 2.0% (down from 3.2% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.3%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Ankündigung • Feb 09
Ambea AB (publ) Proposes Dividend for 2021 The board of Ambea AB (publ) proposed a dividend of SEK 1.15 (1.15) per share for 2021. Reported Earnings • Nov 06
Third quarter 2021 earnings released: EPS kr2.01 (vs kr1.61 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr2.95b (up 7.9% from 3Q 2020). Net income: kr190.0m (up 25% from 3Q 2020). Profit margin: 6.4% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings. Board Change • Aug 04
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Liselott Kilaas was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Ankündigung • May 13
Ambea AB (publ) Approves Dividend, Payable on 20 May 2021 The annual shareholders' meeting of Ambea AB (publ) resolved on a dividend of SEK 1.15 per share. 17 May 2021 was established as record day for dividend. The dividend is expected to be paid out to the shareholders on 20 May 2021. Ankündigung • May 05
Ambea AB (Publ) Provides Revenue Guidance for the Second Quarter of Fiscal Year 2021 Ambea AB (publ) provided revenue guidance for the second quarter of fiscal year 2021. For the quarter, the company expects negative impact on the pandemic or of the pandemic to be SEK 90 million to SEK 100 million on sales. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS kr3.80 (vs kr2.51 in FY 2019) The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: kr11.1b (flat on FY 2019). Net income: kr359.0m (up 67% from FY 2019). Profit margin: 3.2% (up from 1.9% in FY 2019). Recent Insider Transactions • Mar 13
Insider recently sold €145k worth of stock On the 10th of March, Erik Sörensson sold around 20k shares on-market at roughly €7.27 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €480k more than they bought in the last 12 months. Recent Insider Transactions • Feb 19
Insider recently sold €61k worth of stock On the 16th of February, Erik Sörensson sold around 8k shares on-market at roughly €7.50 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €274k more than they bought in the last 12 months. Reported Earnings • Feb 17
Full year 2020 earnings released: EPS kr3.78 (vs kr2.51 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr11.2b (up 1.5% from FY 2019). Net income: kr359.0m (up 67% from FY 2019). Profit margin: 3.2% (up from 1.9% in FY 2019). Analyst Estimate Surprise Post Earnings • Feb 17
Revenue beats expectations Revenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 2.9%, compared to a 3.4% growth forecast for the Healthcare industry in Germany. Is New 90 Day High Low • Feb 12
New 90-day high: €7.23 The company is up 32% from its price of €5.46 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.23 per share. Is New 90 Day High Low • Jan 13
New 90-day high: €6.63 The company is up 20% from its price of €5.53 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.80 per share. Is New 90 Day High Low • Dec 22
New 90-day high: €6.07 The company is up 8.0% from its price of €5.63 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.56 per share. Is New 90 Day High Low • Dec 05
New 90-day high: €5.94 The company is up 8.0% from its price of €5.49 on 04 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.08 per share. Recent Insider Transactions • Nov 12
Division Manager of Vardaga recently sold €221k worth of stock On the 9th of November, Ulla Tansen sold around 39k shares on-market at roughly €5.64 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months. 